| Authors: |
Fiskus W; The University of Texas MD Anderson Cancer Center, Houston, TX., Mill CP; The University of Texas MD Anderson Cancer Center, Houston, TX., Issa GC; The University of Texas MD Anderson Cancer Center, Houston, TX., Piel J; Foghorn Therapeutics, Cambridge, MA., Collins M; Foghorn Therapeutics, Cambridge, MA., Hentemann M; Foghorn Therapeutics, Cambridge, MA., Cuglievan B; The University of Texas MD Anderson Cancer Center, Houston, TX., Hou H; The University of Texas MD Anderson Cancer Center, Houston, TX., Jain A; Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX., Malovannaya A; Mass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, TX., Kadia TM; The University of Texas MD Anderson Cancer Center, Houston, TX., Daver N; The University of Texas MD Anderson Cancer Center, Houston, TX., Sasaki K; The University of Texas MD Anderson Cancer Center, Houston, TX., Takahashi K; The University of Texas MD Anderson Cancer Center, Houston, TX., Hammond D; The University of Texas MD Anderson Cancer Center, Houston, TX., Senapati J; The University of Texas MD Anderson Cancer Center, Houston, TX., Loghavi S; The University of Texas MD Anderson Cancer Center, Houston, TX., Flores LB; The University of Texas MD Anderson Cancer Center, Houston, TX., Su X; The University of Texas MD Anderson Cancer Center, Houston, TX., DiNardo CD; The University of Texas MD Anderson Cancer Center, Houston, TX., Bhalla KN; The University of Texas MD Anderson Cancer Center, Houston, TX. |
